Company Profile

Greenmark Biomedical Inc
Profile last edited on: 5/4/2022            CAGE: 7Q1M7            UEI: KD8DNMPUDDE3

Biobased targeting technologies
Year Founded
2016
1st Award Year
2018
Latest Award
2020
Program Status
Active
Popularity Index

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

325 East Grand River Avenue Suite 314
East Lansing, MI 48823
   (517) 896-3665
   info@greenmark.bio
   www.greenmark.bio
Multiple Locations:   
Congressional District:   08
County:   Ingham

Public Profile

GreenMark is a healthcare company carefully structured to be minimally invasive: developing technologies that involve biopolymer nanoparticles produced from natural starch as a raw material. Starch is degraded by natural enzymes in the human body. Hence, starch nanoparticles are an ideal carrier for various dental and medical applications. The organizing principle of Greenmark therefore is on-target biodelivery of health solutions precisely where they are needed. The firm has patented, patent-pending and proprietary technologies that use different grades of ECO’s biobased nanoparticles and uniquely modifies these into novel products that have built-in targeting performance for diagnostic and therapeutic applications. The developed GreenMark technology utilizes proprietary bio-based nanoparticles as the delivery vehicle: Dental: targeted delivery for diagnosis and treatment of tooth decay (cavities); Medical: targeted Safe, biobased, biocompatible and fully resorbable

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
---
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount Project Title
2020 2 NIH $1,704,542
Bioresorbable Nanoparticles for Visual Detection of Early-Stage Dental Caries

Key People / Management

  Steven Bloembergen -- Founder, Chairman and CEO

  Wendy Bloembergen -- VP Clinical Affairs

  Nathan Jones -- VP of Technology

  Joerg Lahann -- Director and Advisor

  Adam G Laird -- Director of Business Development

  Kenneth J Pienta -- Director and Advisor

  Mike Snyder -- Director and Advisor

  Frank Van Luttikhuizen -- Director and Advisor

  Jae Young Han -- Manager, Clinical Engagement & Customer Relations

SBIR firms in the news

There are no news available.